Rubra Medicaments Ltd Stock Analysis

Small Cap
Evaluated by 57 users | BSE: 531099 | NSE: |

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
Return on Capital Employed -4.49%-1.68%-1.44%-1.59%-47.7%-1.75%8.9%7.68%-22.32%1.84%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 000000.
Y-o-Y Gr. Rt.-NANANANANA55%641.9%-74.4%67.8%
Adjusted EPS (Rs.) -0.31-0.11-0.1-0.11-1.78-
Y-o-Y Gr. Rt.-NANANANANANA16.7%-442.9%NA
Book Value per Share (Rs.) 6.636.516.416.340.710.70.760.470.440.5
Adjusted Net Profit -0.2-0.1-0.1-0.1-1000-0.10
Net Op. Cash Flow (Rs. Cr.) -0.1-0.1-0.1-0.1-0.1000.200.1
Debt to Cash Flow from Ops -1.23-2.02-3.55-4.25000000
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Rubra Medicaments Ltd. should be analysed on a Standalone basis
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NANA47.3%67.8%
Adjusted EPS NANA-30.7%NA
Book Value per Share -25-6.8-1313.6
Share Price -3.4% 7.9% -13% 57%
Key Financial Parameter
Performance Ratio Colour Code Guide
Return on Equity (%) -4.53-1.72-1.5-1.68-50.55-1.758.477.54-22.371.7
Operating Profit Margin (%) -4019.250000-3.4611.21-1.48-30.731.81
Net Profit Margin (%) -4019.250000-3.4811.091.66-22.181.02
Debt to Equity
Working Capital Days 2,95,644000065543767314236
Cash Conversion Cycle 8,375000033-211212294
Entity Percentage Holding
Non-Institutions 100.00%
Pledged *
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Rubra Medicaments Ltd's performance infers:

Rubra Medicaments Ltd earnings have grown by 0%, whereas share price has appreciated 7.9% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Rubra Medicaments Ltd share prices over the last 10 years. Here is what we found out:

Rubra Medicaments Ltd share price has appreciated -7.9% annually over the past ten years.

No data to display
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323